JP2005510573A - 抗生物質ge81112ファクターa、b、b1、その製薬学的に許容され得る塩および組成物および使用 - Google Patents
抗生物質ge81112ファクターa、b、b1、その製薬学的に許容され得る塩および組成物および使用 Download PDFInfo
- Publication number
- JP2005510573A JP2005510573A JP2003547624A JP2003547624A JP2005510573A JP 2005510573 A JP2005510573 A JP 2005510573A JP 2003547624 A JP2003547624 A JP 2003547624A JP 2003547624 A JP2003547624 A JP 2003547624A JP 2005510573 A JP2005510573 A JP 2005510573A
- Authority
- JP
- Japan
- Prior art keywords
- antibiotic
- factor
- acid
- mixture
- streptomyces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 150000003839 salts Chemical class 0.000 title claims abstract description 29
- 230000003115 biocidal effect Effects 0.000 title claims description 45
- 241000187180 Streptomyces sp. Species 0.000 claims abstract description 25
- 238000000855 fermentation Methods 0.000 claims abstract description 21
- 230000004151 fermentation Effects 0.000 claims abstract description 21
- 102000003712 Complement factor B Human genes 0.000 claims abstract description 16
- 108090000056 Complement factor B Proteins 0.000 claims abstract description 16
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 16
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 150000002500 ions Chemical class 0.000 claims description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- 238000001228 spectrum Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 8
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- UZCGKGPEKUCDTF-UHFFFAOYSA-N fluazinam Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=C(Cl)C([N+]([O-])=O)=C1NC1=NC=C(C(F)(F)F)C=C1Cl UZCGKGPEKUCDTF-UHFFFAOYSA-N 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 4
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 claims description 4
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 claims description 4
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 claims description 4
- 238000002329 infrared spectrum Methods 0.000 claims description 4
- 239000003456 ion exchange resin Substances 0.000 claims description 4
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 4
- 238000010829 isocratic elution Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 238000000825 ultraviolet detection Methods 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 claims description 3
- 238000002953 preparative HPLC Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 claims 3
- 238000001819 mass spectrum Methods 0.000 claims 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 9
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 42
- 239000002253 acid Substances 0.000 description 40
- 239000002609 medium Substances 0.000 description 28
- 239000000126 substance Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 14
- 229920001817 Agar Polymers 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 241000187747 Streptomyces Species 0.000 description 12
- 150000004678 hydrides Chemical class 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000186361 Actinobacteria <class> Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000588655 Moraxella catarrhalis Species 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000000887 hydrating effect Effects 0.000 description 3
- -1 hydroxy fatty acids Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920005990 polystyrene resin Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 2
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- IWTBVKIGCDZRPL-UHFFFAOYSA-N 3-methylpentanol Chemical compound CCC(C)CCO IWTBVKIGCDZRPL-UHFFFAOYSA-N 0.000 description 2
- FFWSICBKRCICMR-UHFFFAOYSA-N 5-methyl-2-hexanone Chemical compound CC(C)CCC(C)=O FFWSICBKRCICMR-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000610620 Homo sapiens Putative serine protease 29 Proteins 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100040345 Putative serine protease 29 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101100046603 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TOM6 gene Proteins 0.000 description 2
- 101100397228 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp6 gene Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical group 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 2
- ZOCHHNOQQHDWHG-UHFFFAOYSA-N hexan-3-ol Chemical compound CCCC(O)CC ZOCHHNOQQHDWHG-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920006122 polyamide resin Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- OHEFFKYYKJVVOX-UHFFFAOYSA-N sulcatol Chemical compound CC(O)CCC=C(C)C OHEFFKYYKJVVOX-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001446247 uncultured actinomycete Species 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019143 vitamin K2 Nutrition 0.000 description 2
- 239000011728 vitamin K2 Substances 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- 239000001618 (3R)-3-methylpentan-1-ol Substances 0.000 description 1
- NMRPBPVERJPACX-UHFFFAOYSA-N (3S)-octan-3-ol Natural products CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 239000005968 1-Decanol Substances 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- HMSVXZJWPVIVIV-UHFFFAOYSA-N 2,2-dimethylpentan-3-ol Chemical compound CCC(O)C(C)(C)C HMSVXZJWPVIVIV-UHFFFAOYSA-N 0.000 description 1
- KMVFQKNNDPKWOX-UHFFFAOYSA-N 2,3-dimethylcyclohexan-1-ol Chemical compound CC1CCCC(O)C1C KMVFQKNNDPKWOX-UHFFFAOYSA-N 0.000 description 1
- BAYAKMPRFGNNFW-UHFFFAOYSA-N 2,4-dimethylpentan-3-ol Chemical compound CC(C)C(O)C(C)C BAYAKMPRFGNNFW-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ACUZDYFTRHEKOS-SNVBAGLBSA-N 2-Decanol Natural products CCCCCCCC[C@@H](C)O ACUZDYFTRHEKOS-SNVBAGLBSA-N 0.000 description 1
- WOFPPJOZXUTRAU-UHFFFAOYSA-N 2-Ethyl-1-hexanol Natural products CCCCC(O)CCC WOFPPJOZXUTRAU-UHFFFAOYSA-N 0.000 description 1
- QNVRIHYSUZMSGM-LURJTMIESA-N 2-Hexanol Natural products CCCC[C@H](C)O QNVRIHYSUZMSGM-LURJTMIESA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JEXQWCBPEWHFKC-UHFFFAOYSA-N 2-cyclopentylethanol Chemical compound OCCC1CCCC1 JEXQWCBPEWHFKC-UHFFFAOYSA-N 0.000 description 1
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 1
- RGRUUTLDBCWYBL-UHFFFAOYSA-N 2-methylhexan-3-ol Chemical compound CCCC(O)C(C)C RGRUUTLDBCWYBL-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- DUXCSEISVMREAX-UHFFFAOYSA-N 3,3-dimethylbutan-1-ol Chemical compound CC(C)(C)CCO DUXCSEISVMREAX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IBMXMCXCSPGCDQ-UHFFFAOYSA-N 3-cyclopentylpropan-1-ol Chemical compound OCCCC1CCCC1 IBMXMCXCSPGCDQ-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- OIBKGNPMOMMSSI-UHFFFAOYSA-N 4,4-dimethylpentan-2-ol Chemical compound CC(O)CC(C)(C)C OIBKGNPMOMMSSI-UHFFFAOYSA-N 0.000 description 1
- RVTKUJWGFBADIN-UHFFFAOYSA-N 4-ethylcyclohexan-1-ol Chemical compound CCC1CCC(O)CC1 RVTKUJWGFBADIN-UHFFFAOYSA-N 0.000 description 1
- PCWGTDULNUVNBN-UHFFFAOYSA-N 4-methylpentan-1-ol Chemical compound CC(C)CCCO PCWGTDULNUVNBN-UHFFFAOYSA-N 0.000 description 1
- ZVHAANQOQZVVFD-UHFFFAOYSA-N 5-methylhexan-1-ol Chemical compound CC(C)CCCCO ZVHAANQOQZVVFD-UHFFFAOYSA-N 0.000 description 1
- ZDVJGWXFXGJSIU-UHFFFAOYSA-N 5-methylhexan-2-ol Chemical compound CC(C)CCC(C)O ZDVJGWXFXGJSIU-UHFFFAOYSA-N 0.000 description 1
- 241000187362 Actinomadura Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241000187267 Microtetraspora Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100397225 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp3 gene Proteins 0.000 description 1
- 101100397226 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp4 gene Proteins 0.000 description 1
- 101100397227 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp5 gene Proteins 0.000 description 1
- 101100397229 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp7 gene Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- QHIWVLPBUQWDMQ-UHFFFAOYSA-N butyl prop-2-enoate;methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C.CCCCOC(=O)C=C QHIWVLPBUQWDMQ-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- QCRFMSUKWRQZEM-UHFFFAOYSA-N cycloheptanol Chemical compound OC1CCCCCC1 QCRFMSUKWRQZEM-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- FHADSMKORVFYOS-UHFFFAOYSA-N cyclooctanol Chemical compound OC1CCCCCCC1 FHADSMKORVFYOS-UHFFFAOYSA-N 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- ACUZDYFTRHEKOS-UHFFFAOYSA-N decan-2-ol Chemical compound CCCCCCCCC(C)O ACUZDYFTRHEKOS-UHFFFAOYSA-N 0.000 description 1
- ICEQLCZWZXUUIJ-UHFFFAOYSA-N decan-3-ol Chemical compound CCCCCCCC(O)CC ICEQLCZWZXUUIJ-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- BOZILQFLQYBIIY-INTXDZFKSA-N mevinic acid Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)CCC=C21 BOZILQFLQYBIIY-INTXDZFKSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N n-butyl methyl ketone Natural products CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940097411 palm acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
元々、内部コードGE81112と命名されたストレプトミセス種(Streptomyces sp.)DSMZ14386は土壌サンプルから単離され、そして2001年7月16日にDSMZ(ドイツ国、D−38124 ブラウンシュヴァイグ、マッシェルオーダー通り 1bのドイチェ ザムルング フォン ミクロオーガニズメン ウント ゼルカルチュレン社(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH))にブタペスト条約の規定に基づき寄託された。この菌株は寄託番号DSMZ14386を付与された。
ストレプトミセス種(Streptomyces sp.)DSMZ14386の形態学的特徴
ストレプトミセス種(Streptomyces sp.)DSMZ14386は、多くの標準的な固体培地でよく成長する。微生物学的調査および細胞の寸法は、1/10濃度のフミン酸培地で成長させたカルチャーを使用して測定した(H.Nonomura、1984−土壌放線菌の単離用の新規培地の設計(Design of a new medium for isolation of soil actinomycetes)。The Actionomycetes 18,206−209)。
ストレプトミセス種(Streptomyces sp.)DSMZ14386の培養特性
ストレプトミセス種(Streptomyces sp.)DSMZ14386は、V6液体培地で2日間成長させた(培地組成については実施例1を参照されたい)。菌糸体を遠心により回収し、そして滅菌塩溶液で3回洗浄し、そして次いで希釈して安定な菌種を提供した。懸濁液のアリコートをShirling and Gottlieb(E.B.Shirling and Gottlieb、1966−放線菌種の特性決定法(Method for Characterization of Streptomyces species)−.Int.J.Syst.Bacteriol.,16,313−340)により推薦された種々の培地上、およびWaksman(Waksman S.A.、1961−放線菌(The Actinomycetes)−ウイリアムズ アンド ウィルキンス社(Williams and Wilkins Co.)、ボルチモア、第2巻、第328−334)により推薦される数種の培地上に斜交平行様式で画線した。
表I:ストレプトミセス種(Streptomyces sp.)DSMZ14386の成長特性
培地 成長および形態 反転の
色コード
ISP2 豊富な成長、回旋状、画線のほぼ末端まで 12L9
酵母エキス− 厚くなる;オレンジ/茶色;成長の限界で
麦芽エキス 退色。白色の気中菌糸のふさ状分岐。
寒天 可溶性の色素は生産しない。深い土壌の匂い。
ISP3 滑らかな表面の豊富な成長;クリームから 11H3
オートミール 帯黄色。成長の限界に近い所でのみ白色の
寒天 気中菌糸の薄層。可溶性の色素は生産しない。
ISP4 豊富な成長、回旋状、画線のほぼ末端まで 10F3
無機塩− 厚くなる;帯黄色。白色の気中菌糸の
澱粉 存在、綿状。可溶性の色素は生産しない。
寒天 深い土壌の匂い。
ISP5 分かれて良好に成長;無色から明黄色; 10G2
グリセロール 羽状化および縁で退色。薄い、白色の
−アスパラギン 気中菌糸の存在、古くなる(aging)とピンクになる
寒天 (10A2)。可溶性の色素は生産しない。
ISP6 分かれて成長、画線の末端付近で皺化; 11J3
ペプトン− コロニーの直径は小さい;画線の領域から
酵母エキス 少し広がる;にかわ質;明茶色。気中菌糸は
−鉄寒天 生産しない。培地がわずかに暗化。
ISP7 豊富な成長、回旋状、画線のほぼ末端まで 14L9
チロシン寒天 厚くなる;茶色;羽状化および退色した縁。
白色の気中菌糸の良好な生産、粉末状。
茶色い可溶性色素が生産される。わずかに
土壌の匂い。
SYE 豊富な成長、回旋状、画線のほぼ末端まで 10L7
澱粉− 厚くなる;黄色/茶色;広く、羽状化し、
酵母エキス そして縁で退色。白色の薄い気中菌糸
寒天 のわずかな生産。可溶性色素は生産しない。
わずかに土壌の匂い。
CZ−GLU 分かれて良好に成長、画線のほぼ末端まで厚い; 12H6
Czapeck− コロニーは直径が小さい;クリーム−明茶色;
グルコース 羽状化した縁。白色の薄い気中菌糸
寒天 のわずかな生産。可溶性色素は生産しない。
わずかに土壌の匂い
GAUZE1 成長なし −
寒天
GAUZE2 良好な成長、画線のほぼ末端で薄く、皺がより、 11L6
寒天 そして厚く、画線の交差付近で平ら;帯黄色/
茶色。平坦領域に薄い白色の気中菌糸の
わずかな存在。培地のわずかな暗化。
NA 分かれて良好に成長、滑らか; 11L2
栄養 クリーム/帯黄色。気中菌糸は生産しない。
観点 可溶性色素は生産しない。
SE わずかに見える栄養菌糸体;無色;画線の ND
土壌エキス 領域からわずかに広がる。気中菌糸は
寒天 生産しない。可溶性色素は生産しない。
HV/2 栄養菌糸体が深く寒天に浸透した良好な成長; ND
フミン酸− 暗茶色;羽状化した縁。白色の気中菌糸
ビタミン寒天 の存在、粉末状。
表II:ストレプトミセス種(Streptomyces sp.)DSMZ14386の生理学的特性
試験 反応
澱粉加水分解 陽性
カゼイン加水分解 陰性
マレイン酸カルシウム消化 陽性
リトマス ミルク ペプトン化 陽性(弱い)
リトマス ミルク 凝固 陰性
ゼラチン液化 陽性(弱い)
チロシン反応 陽性
H2S生産(4日): 陰性
ISP6
+酢酸鉛片について わずかに陽性
硝酸塩還元 陰性
NaCl耐性 <7%
表III.ストレプトミセス種(Streptomyces sp.)DSMZ14386による炭素源の利用
炭素源 栄養菌糸体 気中菌糸
の成長 の成長
アラビノース + +/−
フルクトース ++ ++
イノシトール + +/−
マンニトール ++ +
ラフィノース ++ ++
ラムノース ++ ++
シュクロース − +/−
キシロース ++ ++
グルコース ++ −
++良好な成長;+中程度の成長;−わずか/成長なし;
ストレプトミセス種(Streptomyces sp.)DSMZ14386の化学分類的特性
ストレプトミセス種(Streptomyces sp.)DSMZ14386をSautonの培地で4週間成長させ、次いで菌糸体を収穫し、滅菌蒸留水で3回洗浄し、そして続いて凍結乾燥した。ジアミノピメリン酸(DAP)の立体異性体を、Staneck and Robertsの方法(J.L.Staneck and G.D.Roberts、薄層クロマトグラフィーによる好気性放線菌の同定に対する簡略された取り組み(Simplified approach to identification of aerobic actinomycetes by thin−layer chromatography)、Appl.Microbiol.28,226−231,1974)に従い測定した。
ストレプトミセス種(Streptomyces sp.)DSMZ14386株の同一性
化合物GE81112を生産する菌株は、以下の形態学的および化学的特性からストレプトミセス(Streptomyces)属に割り当てられる:
−分岐化されているが断片化されていない栄養菌糸体の形成。気中菌糸は10より多くの(ほとんどが20より多く)の分節胞子を生じる;
−Kroppenstedt(R.M.Kroppenstedt、放線菌および関連微生物の脂肪酸およびメナキノン分析(Fatty acid and menaquinone analysis of actinomycetes and related organism)、pp.173−199:細菌系統における化学的方法(Chemical Methods in bacterial Systematics)で、M.Goodfellow and D.E.Minnikin編集;ロンドン、アカデミック出版、1985)に従う細胞壁中のLL−ジアミノピペリン酸の存在および2c型の脂肪酸プロフィール。
GE81112化合物の抽出および精製
生産微生物の発酵ブロスからのGE81112化合物の回収は、補助剤の存在下で溶媒を用いた抽出、非溶媒、塩を加えることによる沈殿のようなそれ自体は既知の技術に従い、あるいは溶液のpHを変えること、分配クロマトグラフィー、逆相分配クロマトグラフィー、イオン交換クロマトグラフィー、分子排除クロマトグラフィー等により行う。
GE81112ファクターAの物理化学的特性
A)質量分析法
GE81112ファクターAは、Thermofinniganのカリブレーションミックスを使用して、エレクトロスプレー供給源を付けたThermofinnigan LCQデカ装置でのMS実験において、m/z=644にモノプロトン化イオンを与える。エレクトロスプレー条件は:スプレー電圧:4.7kV;キャピラリー温度:250℃;キャピラリー電圧:9V;注入様式5μl/分であった。スペクトルはアセトニトリル:水 50:50(容量/容量)の0.01mg/ml溶液から記録した。
B)赤外分光学
GE81112ファクターAの赤外スペクトルを図2に示す。スペクトルはIFS−48フーリエ変換分光計を用いてヌジョール(nujol mull)として記録した。以下の吸収主要バンド(cm−1)が観察された:3356;2956;2855;2256;2128;1663;1596;1455;1378;1345;1123;1050;1026;1002;825;764。
C)1H−NMRおよび13C−NMR
GE81112ファクターAの600MHzの1H−NMRスペクトル(図3)および150MHzの13C−NMR(図4)を、トリフルオロ酢酸(TFA)添加後にDMSO−d6中で25℃にて記録した。両スペクトルで、精製工程に由来するギ酸によるシグナルが検出された(1H化学シフト8.13および7.07−7.25ppm;13C化学シフト163.0ppm)
表IVおよび表VはファクターAについて観察された1Hおよび13C NMRシグナルを報告する。
A)質量分析法
GE81112ファクターBは、Thermofinniganのカリブレーションミックスを使用して、エレクトロスプレー供給源を付けたThermofinnigan LCQデカ装置でのMS実験において、m/z=659にモノプロトン化イオンを与える。エレクトロスプレー条件は:スプレー電圧:4.7kV;キャピラリー温度:250℃;キャピラリー電圧:9V;注入様式5μl/分であった。スペクトルはアセトニトリル:水 50:50(容量/容量)の0.01mg/ml溶液から記録した。
B)赤外分光学
GE81112ファクターBの赤外スペクトルを図6に示す。スペクトルはIFS−48フーリエ変換分光計を用いてKBrで記録した。以下の吸収主要バンド(cm−1)が観察された:3359;2958;2852;2258;2129;1681;1591;1450;1385;1347;1122;1072;1025;998;765。
C)1H−NMRおよび13C−NMR
GE81112ファクターBの600MHzの1H−NMRスペクトル(図7)および150MHzの13C−NMRスペクトル(図8)を、トリフルオロ酢酸(TFA)添加後にDMSO−d6中で25℃にて記録した。両スペクトルで、精製工程に由来するギ酸によるシグナルが検出された(1H化学シフト8.13および7.07−7.25ppm;13C化学シフト163.0ppm)
表VIおよび表VIIはファクターBについて観察された1Hおよび13C NMRシグナルを報告する。
A)質量分析法
GE81112ファクターB1は、Thermofinniganのカリブレーションミックスを使用して、エレクトロスプレー供給源を付けたThermofinnigan LCQデカ装置でのMS実験において、m/z=658にモノプロトン化イオンを与える。エレクトロスプレー条件は:スプレー電圧:4.7kV;キャピラリー温度:250℃;キャピラリー電圧:9V;注入様式5μl/分であった。スペクトルはアセトニトリル:水 50:50(容量/容量)の0.01mg/ml溶液から記録した。
B)1H−NMRおよび13C−NMR
GE81112ファクターB1の600MHzの1H−NMRスペクトル(図10)および150MHzの13C−NMRスペクトル(図11)を25℃にてDMSO−d6中で記録した。両スペクトルで、精製工程に由来するギ酸によるシグナルが検出された(1H化学シフト8.32ppm;13C化学シフト165.28ppm)
表VIIIおよび表IXはファクターB1について観察された1Hおよび13C NMRシグナルを報告する。
GE81112ファクターA、BおよびB1の抗微生物活性は、クリニカルラボラトリースタンダードのための国家委員会(The National Committee for Clinical Laboratory Standards)(好気的に成長する細菌の抗微生物感受性試験の希釈法(Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically)−第3版;認可された標準。NCCLS文書M7−A3第13巻25号)に従い標準型のU底96ウェルプレートを用いたミクロ希釈法を使用することにより測定した。結果を表10に報告する。
バイアル中に−80℃で保存した種培養物を、以下の組成(g/リットル);グルコース20、肉エキス5、酵母エキス5、ペプトン5、加水分解カゼイン3およびNaCl1.5を有する100mlのV6培地(V6)を含む500mlのエルレンマイヤーフラスコに接種するために使用した。培地は蒸留水で調製し、そしてpHをNaOHで7.5に調整した後、120℃で20分間滅菌した。接種したフラスコは40〜48時間、28℃で200rpmのロータリーシェーカー上でインキューベーションし、そして次いで3リットルのV6培地を含有する4リットルのバイオリアクターに接種するために使用した。培養は最初の30時間は27℃の温度で成長させ、そして次に後の18時間を24℃で接種時間まで成長させた。撹拌は0.5容量/容量/分の通気で700rpmに維持した。培養物(1.5リットル)は、以下の組成(g/リットル);グリセロール30、ダイズ粉15、炭酸カルシウム5および塩化ナトリウム2を有する200リットルの生産培地を含有する300リットルの発酵槽に接種した。培地は脱イオン水で調製し、そしてpHはNaOHで7.3に調整した。30mlのHodag AFM−5を消泡剤として加えた。この培養物を28℃にて62時間発酵し、最初の18時間は60リットル/分の通気で、そして次いで100リットル/分(0.5容量/容量/分)に収穫時間まで上げた。撹拌は180rpmであった。
実施例1で得た溶液を、1.2リットルのポリスチレン樹脂HP20(三菱化学社)とバッチ様式で一晩撹拌した。次いで樹脂を濾過により回収し、そして7.5cm直径/27cmのベット高カラムに乗せた。次いでカラムは40ml/分の流速で6リットルの1:9(容量/容量)メタノール:蒸留水で、次いで4リットルの3:7(容量/容量)混合物で溶出した。1リットルの画分を集め、そしてHPLCにより分析した。最初の3つの画分はGE81112ファクターAが濃縮されたGE81112ファクターの混合物が含まれ、そしてこれをプールした。以下の3つの画分はファクターB1およびBが濃縮され、そしてこれらもプールした。2つのプールを真空下で濃縮して小容量とし、そして次に凍結乾燥させてファクターAおよびファクターB1に加えてBが濃縮されたそれぞれ3.8grおよび1.7grの固体を得た。
Claims (14)
- A)スプレー電圧:4.7kV;キャピラリー温度:250℃;キャピラリー電圧:9V;注入様式5μl/分のエレクトロスプレー条件下にて、Thermofinnigan LCQデカ装置上でアセトニトリル:水 50:50中の0.01mg/ml溶液から記録される644m/zにモノプロトン化イオンを与える質量スペクトル
B)3356;2956;2855;2256;2128;1663;1596;1455;1378;1345;1123;1050;1026;1002;825;764の主バンド(cm−1)を示すIFS−48フーリエ変換分光計を用いてヌジョールとして記録される赤外スペクトル(図2)
C)DMSO−d6およびトリフルオロ酢酸(数滴)中にて25℃で600MHzで記録される以下の1Hシグナル:
D)DMSO−d6およびトリフルオロ酢酸(数滴)中にて5℃で150MHzで記録される以下の13Cシグナル
E)“Altima”RP18、5μm、250×4.6mm i.dカラムを備えた分析用HPLC 島津LC10−AS;1ml/分流速、ギ酸の添加によりpH4.5とした40mM ギ酸アンモニウムバッファーを用いて行うイソクラティック溶出;230nmでのUV検出を使用することにより測定される保持時間14.1分
の特性を有する抗生物質GE81112ファクターA。 - A)スプレー電圧:4.7kV;キャピラリー温度:250℃;キャピラリー電圧:9V;注入様式5μl/分のエレクトロスプレー条件下にて、Thermofinnigan LCQデカ装置上でアセトニトリル:水 50:50中の0.01mg/ml溶液から記録される659m/zにモノプロトン化イオンを与える質量スペクトル
B)3359;2958;2852;2258;2129;1681;1591;1450;1385;1347;1122;1072;1025;998;765の主バンド(cm−1)を示すIFS−48フーリエ変換分光計を用いて記録されるKBr中での赤外スペクトル(図6)
C)DMSO−d6およびトリフルオロ酢酸(数滴)中にて25℃で600MHzで記録される以下の1Hシグナル:
D)DMSO−d6およびトリフルオロ酢酸(数滴)中にて25℃で150MHzで記録される以下の13Cシグナル
E)“Altima”RP18、5μm、250×4.6mm i.dカラムを備えた分析用HPLC 島津LC10−AS;1ml/分流速、ギ酸の添加によりpH4.5とした40mM ギ酸アンモニウムバッファーを用いて行うイソクラティック溶出;230nmでのUV検出を使用することにより測定される保持時間21.6分
の特性を有する抗生物質GE81112ファクターB。 - A)スプレー電圧:47kV;キャピラリー温度:250℃;キャピラリー電圧:9V;注入様式5l/分のエレクトロスプレー条件下にて、Thermofinnigan LCQデカ装置上でアセトニトリル:水 50:50中の0.01mg/ml溶液から記録される658m/zにモノプロトン化イオンを与える質量スペクトル
B)DMSO−d6中にて25℃で600MHで記録される以下の1Hシグナル:
C)DMSO−d6中にて25℃で150MHzで記録される以下の13Cシグナル:
D)“Altima”RP18、5μm、250×4.6mm i.dカラムを備えた分析用HPLC 島津LC10−AS;1ml/分流速、ギ酸の添加によりpH4.5とした40mM ギ酸アンモニウムバッファーを用いて行うイソクラティック溶出;230nmでのUV検出を使用することにより測定される保持時間18.4分、
の特性を有する抗生物質GE81112ファクターB1。 - 請求項1ないし3のいずれかに記載のGE81112抗生物質を生産する方法であって;
−炭素、窒素および無機塩の同化可能な供給源を含んでなる水性栄養培地中で好気的条件下で、ストレプトミセス種(Streptomyces sp.)DSMZ14386またはGE81112抗生物質を生産する遺伝的能力を維持しているその変種もしくは突然変異体を培養し;
−生成した抗生物質混合物を発酵ブロスから回収し;
−回収した抗生物質混合物を精製し、そして3種の抗生物質GE81112ファクターA、BおよびB1を分離する、
ことを含んでなる上記生産方法。 - 任意の比率の請求項1ないし3に記載の2以上の抗生物質GE81112ファクターおよび製薬学的に許容され得るそれらの塩の混合物。
- 上記の抗生物質GE81112ファクター混合物がストレプトミセス種(Streptomyces sp.)DSMZ14386または該GE81112抗生物質を生産する遺伝的能力を維持するそのGE81112抗生物質生産変種もしくは突然変異体の発酵ブロスから単離されたものである、請求項5に記載の任意の比率の抗生物質GE81112ファクターの混合物。
- 請求項6に記載の抗生物質GE81112ファクターの混合物を生産する方法であって:
−ストレプトミセス種(Streptomyces sp.)DSMZ14386または該GE81112抗生物質を生産する遺伝的能力を維持しているその変種もしくは突然変異体を培養し;
−生成したGE81112ファクターの抗生物質混合物を培養ブロスから回収し;そして−抗生物質GE81112ファクターの該混合物を精製する、
ことを含んでなる上記生産方法。 - ストレプトミセス種(Streptomyces sp.)DSMZ14386、またはGE81112抗生物質を生産する遺伝的能力を維持しているその変種もしくは突然変異体を前培養する、請求項4および7のいずれかに記載する方法。
- 回収がイオン交換樹脂で行われ、そして精製が吸着支持体、好ましくはポリスチレンまたは混合ポリスチレン−ジビニルベンゼン樹脂で行われる、請求項4および7のいずれかに記載の方法。
- 抗生物質GE81112ファクターA、BおよびB1の分離がクロマトグラフィー技法により行われる、請求項4に記載の方法。
- クロマトグラフィー技法が調製用HPLC技法である、請求項10に記載の方法。
- 請求項1ないし3および5のいずれかに記載の抗生物質を含んでなる製薬学的組成物。
- 製薬学的に許容されうる担体を含んでなる請求項12に記載の製薬学的組成物。
- バクテリアの感染を処置する薬剤を製造するための請求項1ないし3および5のいずれかに記載の抗生物質の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01128204 | 2001-11-28 | ||
EP01128204.3 | 2001-11-28 | ||
PCT/EP2002/011113 WO2003046192A1 (en) | 2001-11-28 | 2002-10-04 | Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005510573A true JP2005510573A (ja) | 2005-04-21 |
JP2005510573A5 JP2005510573A5 (ja) | 2005-12-22 |
JP4452505B2 JP4452505B2 (ja) | 2010-04-21 |
Family
ID=8179366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003547624A Expired - Fee Related JP4452505B2 (ja) | 2001-11-28 | 2002-10-04 | 抗生物質ge81112ファクターa、b、b1、その製薬学的に許容され得る塩および組成物および使用 |
Country Status (22)
Country | Link |
---|---|
US (3) | US7407654B2 (ja) |
EP (1) | EP1448784B1 (ja) |
JP (1) | JP4452505B2 (ja) |
KR (1) | KR20040099257A (ja) |
CN (1) | CN1596312A (ja) |
AT (1) | ATE390490T1 (ja) |
AU (2) | AU2002365433A1 (ja) |
BR (1) | BR0214494A (ja) |
CA (1) | CA2468400A1 (ja) |
DE (1) | DE60225834T2 (ja) |
ES (1) | ES2299635T3 (ja) |
HR (1) | HRP20040471A2 (ja) |
HU (1) | HUP0402383A3 (ja) |
IL (1) | IL161896A0 (ja) |
MX (1) | MXPA04005032A (ja) |
NO (1) | NO20042181L (ja) |
NZ (1) | NZ533732A (ja) |
PL (1) | PL370451A1 (ja) |
RU (1) | RU2004119432A (ja) |
WO (1) | WO2003046192A1 (ja) |
YU (1) | YU46804A (ja) |
ZA (1) | ZA200403675B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL370451A1 (en) * | 2001-11-28 | 2005-05-30 | Vicuron Pharmaceuticals Inc. | Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof |
EP3648740A1 (en) | 2017-07-07 | 2020-05-13 | EpicentRx, Inc. | Compositions for parenteral administration of therapeutic agents |
KR102408301B1 (ko) * | 2020-03-16 | 2022-06-10 | 강원대학교산학협력단 | 항균 활성을 갖는 신균주 스트렙토마이세스 sbc-4 및 이의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5043353A (en) | 1989-10-10 | 1991-08-27 | Eli Lilly And Company | A80789 polyether antibiotic |
DK0675900T3 (da) | 1992-12-22 | 1998-03-09 | Biosearch Italia Spa | Antibiotika GE 37468 A, B og C |
US5432193A (en) | 1993-05-14 | 1995-07-11 | American Cyanamid Company | Antibiotic LL-D37187α |
US5426108A (en) * | 1993-11-10 | 1995-06-20 | American Cyanamid Company | Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2 |
US5486630A (en) | 1994-09-14 | 1996-01-23 | Cheil Foods & Chemicals Inc. | Legionella specific antibiotic |
PL370451A1 (en) * | 2001-11-28 | 2005-05-30 | Vicuron Pharmaceuticals Inc. | Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof |
-
2002
- 2002-10-04 PL PL02370451A patent/PL370451A1/xx not_active Application Discontinuation
- 2002-10-04 EP EP02803759A patent/EP1448784B1/en not_active Expired - Lifetime
- 2002-10-04 WO PCT/EP2002/011113 patent/WO2003046192A1/en active IP Right Grant
- 2002-10-04 AT AT02803759T patent/ATE390490T1/de not_active IP Right Cessation
- 2002-10-04 MX MXPA04005032A patent/MXPA04005032A/es not_active Application Discontinuation
- 2002-10-04 YU YU46804A patent/YU46804A/sh unknown
- 2002-10-04 RU RU2004119432/13A patent/RU2004119432A/ru not_active Application Discontinuation
- 2002-10-04 ES ES02803759T patent/ES2299635T3/es not_active Expired - Lifetime
- 2002-10-04 CA CA002468400A patent/CA2468400A1/en not_active Abandoned
- 2002-10-04 IL IL16189602A patent/IL161896A0/xx unknown
- 2002-10-04 DE DE60225834T patent/DE60225834T2/de not_active Expired - Lifetime
- 2002-10-04 HU HU0402383A patent/HUP0402383A3/hu unknown
- 2002-10-04 AU AU2002365433A patent/AU2002365433A1/en not_active Abandoned
- 2002-10-04 JP JP2003547624A patent/JP4452505B2/ja not_active Expired - Fee Related
- 2002-10-04 US US10/496,009 patent/US7407654B2/en not_active Expired - Fee Related
- 2002-10-04 KR KR10-2004-7008079A patent/KR20040099257A/ko not_active Application Discontinuation
- 2002-10-04 BR BR0214494-8A patent/BR0214494A/pt not_active IP Right Cessation
- 2002-10-04 NZ NZ533732A patent/NZ533732A/en unknown
- 2002-10-04 CN CNA02823720XA patent/CN1596312A/zh active Pending
-
2004
- 2004-05-13 ZA ZA200403675A patent/ZA200403675B/xx unknown
- 2004-05-26 NO NO20042181A patent/NO20042181L/no not_active Application Discontinuation
- 2004-05-27 HR HR20040471A patent/HRP20040471A2/xx not_active Application Discontinuation
-
2008
- 2008-06-26 US US12/147,215 patent/US8007789B2/en not_active Expired - Fee Related
- 2008-12-08 AU AU2008255202A patent/AU2008255202A1/en not_active Abandoned
-
2011
- 2011-08-05 US US13/198,754 patent/US20110286996A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008255202A1 (en) | 2009-01-08 |
HUP0402383A3 (en) | 2008-03-28 |
CA2468400A1 (en) | 2003-06-05 |
US7407654B2 (en) | 2008-08-05 |
DE60225834T2 (de) | 2009-04-09 |
RU2004119432A (ru) | 2006-01-10 |
YU46804A (sh) | 2006-08-17 |
US20050020514A1 (en) | 2005-01-27 |
JP4452505B2 (ja) | 2010-04-21 |
EP1448784A1 (en) | 2004-08-25 |
ES2299635T3 (es) | 2008-06-01 |
BR0214494A (pt) | 2004-10-19 |
PL370451A1 (en) | 2005-05-30 |
IL161896A0 (en) | 2005-11-20 |
DE60225834D1 (de) | 2008-05-08 |
US8007789B2 (en) | 2011-08-30 |
NO20042181L (no) | 2004-08-04 |
US20090023665A1 (en) | 2009-01-22 |
AU2002365433A1 (en) | 2003-06-10 |
EP1448784B1 (en) | 2008-03-26 |
WO2003046192A1 (en) | 2003-06-05 |
KR20040099257A (ko) | 2004-11-26 |
US20110286996A1 (en) | 2011-11-24 |
CN1596312A (zh) | 2005-03-16 |
ATE390490T1 (de) | 2008-04-15 |
ZA200403675B (en) | 2005-05-13 |
NZ533732A (en) | 2005-05-27 |
MXPA04005032A (es) | 2004-08-11 |
HUP0402383A2 (hu) | 2005-02-28 |
HRP20040471A2 (en) | 2004-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO164111B (no) | Fremgangsmaate for fremstilling av et antibiotisk virksomta 40926-kompleks og dets rene faktorer pa, pb, a, b og bomikron. | |
KR960010557B1 (ko) | 항생물질 a 40926 n-아실아미노글루쿠로닐 아글리콘 및 항생물질 a 40926 아글리콘 | |
KR100896826B1 (ko) | 항생제 107891, 그의 팩터 a1 및 a2, 제약학상허용되는 염 및 조성물, 및 그의 용도 | |
US5322777A (en) | Antibiotic GE 2270 | |
US4918054A (en) | Antibiotics called `chloropolysporins B and C`, a process for their preparation, and their therapeutic and veterinary use | |
EP0451486B1 (en) | Antibiotic GE 2270 factors B1, B2, C1, C2, D1, D2,E and T | |
US8007789B2 (en) | Antibiotics GE 81112 factors A, B, B1, pharmaceutically acceptable salts and compositions, and use thereof | |
EP0675900B1 (en) | Antibiotics ge 37468 a, b and c | |
RU2228337C2 (ru) | Ванкорезмицин (варианты), его использование, штамм amycolatopsis вида hil-006734 для его получения | |
EP0359062B1 (en) | Antibiotic GE 2270 | |
FI101402B (fi) | Menetelmä uuden antibiootin, balhimysiinin valmistamiseksi | |
US6586393B2 (en) | Antibiotics GE 23077, pharmaceutically acceptable salts and compositions, and use thereof | |
JPH02258774A (ja) | 杭生物質a80915およびその製造法 | |
KR100892655B1 (ko) | 항생제 107891, 그의 팩터 a1 및 a2, 제약학상허용되는 염 및 조성물, 및 그의 용도 | |
EP1213298A1 (en) | Antibiotics GE 23077, pharmaceutically acceptable salts and compositions, and use thereof | |
TW200409816A (en) | Antibiotics GE 81112 factors A,B,B1, pharmaceutically acceptable salts and compositions, and use thereof | |
JPWO2005090384A1 (ja) | K01−0509物質およびその製造法 | |
Bombay et al. | EUROPEAN PATENT APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080909 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090127 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091029 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100126 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100201 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130205 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |